ACRIVON THERAPEUTICS ANNOUNCES FDA HAS GRANTED BREAKTHROUGH DEVICE DESIGNATION FOR ACR-368 ONCOSIGNATURE ASSAY FOR ENDOMETRIAL CANCER

Reuters · 02/05 13:00

Please log in to view news